

| Package | Price per Dose | Price | |
|---|---|---|---|
| 120 pills | £4.74 | £711.38 £569.11 Free shipping | |
| 92 pills | £5.07 | £582.17 £465.73 Free shipping | |
| 90 pills | £5.07 | £569.39 £455.51 Free shipping | |
| 60 pills | £5.13 | £384.79 £307.83 Free shipping | |
| 36 pills | £5.30 | £238.54 £190.83 Free shipping | |
| 24 pills | £5.53 | £166.12 £132.90 | |
| 12 pills | £6.53 | £97.96 £78.37 | |
| 90 pills | £7.28 | £819.30 £655.44 Free shipping | |
| 60 pills | £7.61 | £570.81 £456.65 Free shipping | |
| 36 pills | £8.96 | £403.25 £322.60 Free shipping | |
| 24 pills | £9.51 | £285.40 £228.32 Free shipping | |
| 12 pills | £10.03 | £150.50 £120.40 | |
| 60 pills | £6.93 | £519.69 £415.75 Free shipping | |
| 36 pills | £7.01 | £315.22 £252.17 Free shipping | |
| 24 pills | £7.15 | £214.40 £171.52 Free shipping | |
| 20 pills | £7.33 | £183.16 £146.53 | |
| 12 pills | £7.38 | £110.74 £88.59 | |
| 8 pills | £7.52 | £75.24 £60.19 | |
| 4 pills | £7.67 | £38.32 £30.66 |
Avanafil is a selective phosphodiesterase type 5 (PDE5) inhibitor that enhances nitric oxide–mediated cyclic guanosine monophosphate (cGMP) signaling, promoting penile vasodilation in response to sexual stimulation. It is approved for the treatment of erectile dysfunction in adult men.
As a PDE5 inhibitor, avanafil shows relative selectivity for PDE5 with limited activity at other phosphodiesterases, contributing to a favorable safety profile. It belongs to the on-demand class of therapies and is generally taken before anticipated sexual activity.
Avanafil is indicated for the treatment of erectile dysfunction in adult men, facilitating achievement and maintenance of an erection sufficient for satisfactory sexual intercourse.
Onset is rapid in many patients, with symptom improvement commonly reported within 15 to 30 minutes after dosing when taken as directed. It does not act without sexual stimulation and should be used as needed rather than on a fixed schedule.
Contraindications include concurrent use with nitrates or nitrite-containing medications due to the risk of profound and potentially life-threatening hypotension. Avanafil should not be used in combination with nitrates, nitroprusside, or other NO-donor therapies.
Cardiovascular caution: patients with significant cardiovascular disease, including symptomatic hypotension, recent myocardial infarction, stroke, or decompensated heart failure, should not start avanafil until stabilized. A comprehensive cardiovascular assessment is advised before prescribing, and patients should avoid sudden blood pressure changes.
Ocular safety and systemic considerations: rare NAION reports have been associated with PDE5 inhibitors; patients with prior NAION or risk factors should be informed about sudden vision changes and discontinue use if vision loss occurs. Hepatic and renal impairment should be considered, as avanafil is metabolized by CYP3A4; severe hepatic impairment increases systemic exposure and may be a relative contraindication, with caution also advised in moderate renal impairment and more so in severe renal impairment.
Common: headache, flushing, nasal congestion, back pain, dyspepsia, dizziness.
Uncommon to rare: dizziness related to hypotension, palpitations, facial edema, visual disturbances (increased brightness, blurred vision), tinnitus; rare events include priapism and sudden hearing or vision loss. Seek urgent medical attention for an erection lasting more than 4 hours.
Nitrates and nitric oxide donors are contraindicated with avanafil because coadministration can cause dangerous hypotension. Do not co-prescribe with nitroglycerin, isosorbide dinitrate, nitroprusside, or any nitrate-containing product.
CYP3A4 interactions and antihypertensives: avanafil is metabolized primarily by CYP3A4; potent inhibitors (e.g., ketoconazole, ritonavir) increase exposure and may require dose reduction or avoidance; inducers may decrease efficacy. Co-administration with alpha-blockers or other antihypertensives requires cautious use and monitoring. Hepatic impairment increases exposure and may necessitate avoidance or adjustment in severe cases.
14–21 days. Free from £151.46 .
5–9 days. £22.72
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
